Maria Trachana
A5017854572- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Kawasaki Disease and Coronary Complications
- Immune Cell Function and Interaction
- Renal Diseases and Glomerulopathies
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Family and Disability Support Research
- Ocular Diseases and Behçet’s Syndrome
- Atherosclerosis and Cardiovascular Diseases
- Diabetes and associated disorders
- Spondyloarthritis Studies and Treatments
- Liver Diseases and Immunity
- Cardiovascular Disease and Adiposity
- Orthopedic Infections and Treatments
- Hemoglobinopathies and Related Disorders
- Pharmaceutical studies and practices
- Protein Tyrosine Phosphatases
- Pediatric health and respiratory diseases
- IL-33, ST2, and ILC Pathways
Aristotle University of Thessaloniki
2015-2025
Ryhov Hospital Jönköping
2024
Uppsala University
2024
Ippokrateio General Hospital of Thessaloniki
2015-2023
Hippocration General Hospital
2013-2020
Istituto Giannina Gaslini
2014-2018
Istituti di Ricovero e Cura a Carattere Scientifico
2015
Athens Medical Center
2014
Foundation for Ichthyosis and Related Skin Types
2001
Objective To update the 2012 EULAR/ERA–EDTA recommendations for management of lupus nephritis (LN). Methods Following EULAR standardised operating procedures, a systematic literature review was performed. Members multidisciplinary Task Force voted independently on their level agreeement with formed statements. Results The changes include treatment targets, use glucocorticoids and calcineurin inhibitors (CNIs) end-stage kidney disease (ESKD). target therapy is complete response (proteinuria...
<h3>Objectives</h3> Systemic lupus erythematosus (SLE) diagnosis and treatment remain empirical the molecular basis for its heterogeneity elusive. We explored genomic disease susceptibility severity. <h3>Methods</h3> mRNA sequencing genotyping in blood from 142 patients with SLE 58 healthy volunteers. Abundances of cell types were assessed by CIBERSORT cell-specific effects interaction terms linear models. Differentially expressed genes (DEGs) used to train classifiers (linear discriminant...
Objectives Autoinflammatory diseases cause systemic inflammation that can result in damage to multiple organs. A validated instrument is essential quantify individual patients and compare disease outcomes clinical studies. Currently, there no such tool. Our objective was develop a common autoinflammatory index (ADDI) for familial Mediterranean fever, cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated fever syndrome mevalonate kinase deficiency. Methods We...
Hereditary recurrent fevers (HRF) are a group of rare monogenic diseases leading to inflammatory flares. A large number variants has been described for the four genes associated with best known HRF, namely MEFV, NLRP3, MVK, TNFRSF1A. The Infevers database ( http://fmf.igh.cnrs.fr/ISSAID/infevers ) is international registry collecting reported in these genes. However, no genotype-phenotype associations provided, but only clinical phenotype first patient(s) each mutation. aim this study...
Abstract Objective The aim of this study was to report the interim 5-year safety and effectiveness abatacept in patients with JIA PRINTO/PRCSG registry. Methods Abatacept Registry (NCT01357668) is an ongoing observational children receiving abatacept; enrolment started January 2013. Clinical sites enrolled starting or currently abatacept. Eligible were assessed for (primary end point) over 10 years. Effectiveness measured by clinical 10-joint Juvenile Arthritis Disease Activity Score...
To investigate whether T-bet+ B cells, as well age-associated cells/ABCs (CD19+CD21-CD11c+T-bet+) and double-negative cells/DN (CD19+IgD-CD27- CXCR5-T-bet+), serve prognostic and/or therapeutic tools for systemic lupus erythematosus (SLE) in humans. Flow cytometry was used enumerating cells ABCs/DN subsets, found the peripheral blood of 10 healthy donors 22 active SLE patients. Whole assay cultures, combined with vitro pharmacological treatments, were performed to evaluate effects...
To our knowledge, limited information is available about the differences in characteristics of rheumatoid factor (RF)-negative polyarticular juvenile idiopathic arthritis (JIA) throughout world. This study was aimed to compare demographic and clinical features patients with RF-negative polyarthritis across Patients were part a multinational sample included investigate prevalence disease categories, treatment regimens, status from different geographical areas (EPOCA Study). All underwent...
Objectives: To evaluate the safety and efficacy of adalimumab (AD) administration in patients with juvenile idiopathic arthritis (JIA).Methods: Twenty-six were enrolled from January 2004 to 2008 this prospective observational study. Inclusion criteria either unresponsiveness disease-modifying anti-rheumatic drugs (DMARDs; n = 17) or other anti-tumour necrosis factor (anti-TNF) agents (n 9) development uveitis under anti-TNFs 2 9). Efficacy was estimated using American College Rheumatology...
<h3>Introduction</h3> Autoinflammatory diseases can cause irreversible tissue damage due to systemic inflammation. Recently, the Disease Damage Index (ADDI) was developed. The ADDI is first instrument quantify in familial Mediterranean fever, cryopyrin-associated periodic syndromes, mevalonate kinase deficiency and tumour necrosis factor receptor-associated syndrome. aim of this study validate tool for its intended use a clinical/research setting. <h3>Methods</h3> scored on paper clinical...
Objective To evaluate the long‐term efficacy and safety of canakinumab explore prediction response in patients with systemic juvenile idiopathic arthritis (JIA) or without fever at treatment initiation. Methods At enrollment, active JIA (ages 2 to <20 years) started open‐label (4 mg/kg every 4 weeks subcutaneously). Efficacy measures included adapted American College Rheumatology (ACR) Pediatric 50/70/90 criteria, Juvenile Arthritis Disease Activity Score (JADAS), clinically inactive...
To describe the disease characteristics, continuous course and long-term outcome to evaluate predictors of in JIA Greece.We performed a retrospective cohort analysis 17 years' prospective data on JIA. Outcome assessment included radiographic (modified Sharp-van der Heidje score), articular extra-articular damage (Juvenile Arthritis Damage Index), functional ability (HAQ Disability cumulative percentage time spent state active also clinical remission off medication (CR) (according Wallace's...
We investigated the simultaneous changes in serum levels of HMGB1 and IFN-α as well LAIR-1 expression on plasmatoid dendritic cells (pDCs) juvenile systemic lupus erythematosus (jSLE) patients order to explore their involvement disease pathogenesis correlation with activity other characteristics. In total, 62 blood samples were studied from 26 jSLE (18 girls), aged 8-16 years. Twenty healthy subjects (16 girls) comparable age included controls (HCs). Concentrations assessed by ELISA pDCs...
Objective To develop a standardized steroid dosing regimen (SSR) for physicians treating childhood‐onset systemic lupus erythematosus (SLE) complicated by nephritis (LN), using consensus formation methodology. Methods Parameters influencing corticosteroid (CS) were identified (step 1). Data from children with proliferative LN used to generate patient profiles 2). Physicians rated changes in renal and extrarenal SLE activity between 2 consecutive visits proposed CS 3). The SSR was developed...
The discovery of serum biomarkers specific for paediatric lupus nephritis (pLN) will facilitate the non-invasive diagnosis, follow-up and more appropriate use treatment. aim this study was to explore role high-mobility group box 1 (HMGB1) protein, antibodies against nucleosomes (anti-NCS), complement factor C1q (anti-C1q) glomerular basement membrane (anti-GBM) in pLN. Serum samples 42 patients with systemic erythematosus (pSLE) (22 pLN 20 without renal involvement), 15 other autoimmune (AN)...
To evaluate safety and effectiveness of adalimumab (ADA) in polyarticular-course juvenile idiopathic arthritis (JIA) the STRIVE registry.STRIVE enrolled patients with JIA into 2 arms based on treatment methotrexate (MTX) alone or ADA with/without MTX (ADA ± MTX). Adverse events (AEs) per 100 patient-years observation time were analyzed by registry arm. Patients who entered within 4 weeks starting MTX, defined as new users, evaluated for change disease activity assessed 27-joint Juvenile...
To develop parent- and child-centered versions of the Juvenile Arthritis Disease Activity Score (JADAS) to provide preliminary evidence their validity.